BrayGA. Definition, measurement and classification of the syndromes of obesity. In: BrayGA, ed. Kroc Foundation Symposium on comparative methods of weight control. Obesity. London: John Libbey, 1979: 1–14.
2.
MeyboomRHBRoyerRJ. Causality classification at pharmacovigilance centres in the European community. Pharmacoepidemiol Drug Saf1992; 1: 87–9.
3.
Propranolol for prevention of migraine headaches. Med Lett Drugs Ther1979; 21: 77–8.
4.
GallowayDBGloverSCHendryWGLogieAWPetneYCSmithMCPropranolol in hypertension: A dose-response study. Br Med J1976; 2: 140–2.
5.
VlachakisMDMendlowitzM. An approach to the treatment of essential hypertension. Am Heart J1976; 92: 750–7.
6.
HelgelandAHjermannILerenPHolmeI. Possible metabolic side effects of beta-adrenergic blocking drugs. Br Med J1978; 1: 828.
7.
RössnerSTaylorCLByingtonRPFurbergCD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ1990; 300: 902–3.
8.
ReynoldsJEF, ed. Martindale the extra pharmacopeia. 29th ed.London: The Pharmaceutical Press, 1989: 798–807.